Skip to content

A Clinical Efficacy Study on Warming Yang and Resolving Depression Therapy for Patients with Depression Accompanied by Fatigue Symptoms

Clinical Efficacy and Safety of Warming Yang and Resolving Depression Therapy (Core Formula: Baihe Ningshen Granules) for Depression with Fatigue Symptoms: A Randomized, Double-blind, Placebo-controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000568
Enrollment
Unknown
Registered
2026-03-18
Start date
2025-11-20
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression with fatigue symptoms

Interventions

Treatment Group:Warming Yang and Resolving Depression decoction granules (twice daily, one bag per dose) combined with escitalopram
Control Group:TCM simulation placebo (dextrin + bitter principle) combined with the same dose of escitalopram

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for a depressive episode; present with fatigue symptoms (FS-14 score =6); have mild to moderate depression (HAMD-17 score: 7-24 points); be diagnosed with the TCM pattern of Kidney Deficiency and Liver Depression according to the "TCM Syndrome Scale for Kidney Deficiency and Liver Depression Pattern"; aged 18-60 years, gender; provide signed informed consent (legal guardians must provide proof of relationship if signing on behalf of the participant).

Exclusion criteria

Exclusion criteria: Pregnant or lactating women; organic brain disorders, psychoactive substance abuse, or comorbid other psychiatric disorders; high suicide risk (Item 3 of HAMD =3 points); known allergy or intolerance to the study drugs (TCM granules or escitalopram); severe hepatic or renal insufficiency (ALT/AST >2 times the upper limit of normal, Cr >1.5 times the upper limit of normal); participation in other clinical trials within the past month.

Design outcomes

Primary

MeasureTime frame
Fatigue Scale-14 (FS-14) Score;

Secondary

MeasureTime frame
Hamilton Depression Rating Scale-17 (HAMD-17) Score;TCM Syndrome Scale Score for Kidney Deficiency and Liver Depression Pattern;Hamilton Anxiety Rating Scale (HAMA) Score;Clinical Global Impression - Severity (CGI-S) Score;Personal and Social Performance scale - Chinese Version (PSP-CHN) Score;

Countries

China

Contacts

Public ContactYin Dongqing

Beijing Anding Hospital, Capital Medical University

yindq1123@163.com13811005469

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026